1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57:43–66.
Article
2. Catrysse L, Vereecke L, Beyaert R, van Loo G. A20 in inflammation and autoimmunity. Trends Immunol. 2014; 35:22–31.
Article
3. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003; 60:387–92.
Article
4. Brunnstrom H, Gustafson L, Passant U, Englund E. Prevalence of dementia subtypes: a 30-year retrospective survey of neuropathological reports. Arch Gerontol Geriatr. 2009; 49:146–9.
Article
5. Wolters FJ, Chibnik LB, Waziry R, Anderson R, Berr C, Beiser A, et al. Twenty-seven-year time trends in dementia incidence in Europe and the United States: the Alzheimer Cohorts Consortium. Neurology. 2020; 95:e519–31.
6. Lu H, Wang XD, Shi Z, Yue W, Zhang Y, Liu S, et al. Comparative analysis of cognitive impairment prevalence and its etiological subtypes in a rural area of northern China between 2010 and 2015. Sci Rep. 2019; 9:851.
Article
7. Catala-Lopez F, Suarez-Pinilla M, Suarez-Pinilla P, Valderas JM, Gomez-Beneyto M, Martinez S, et al. Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies. Psychother Psychosom. 2014; 83:89–105.
Article
8. Yarchoan M, James BD, Shah RC, Arvanitakis Z, Wilson RS, Schneider J, et al. Association of cancer history with Alzheimer’s disease dementia and neuropathology. J Alzheimers Dis. 2017; 56:699–706.
Article
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646–74.
Article
10. Shafi O. Inverse relationship between Alzheimer’s disease and cancer, and other factors contributing to Alzheimer’s disease: a systematic review. BMC Neurol. 2016; 16:236.
Article
11. Nudelman KNH, McDonald BC, Lahiri DK, Saykin AJ. Biological hallmarks of cancer in Alzheimer’s disease. Mol Neurobiol. 2019; 56:7173–87.
Article
12. Nixon DW. The inverse relationship between cancer and Alzheimer’s disease: a possible mechanism. Curr Alzheimer Res. 2017; 14:883–93.
Article
13. Lin HL, Lin HC, Tseng YF, Chen SC, Hsu CY. Inverse association between cancer and dementia: a population-based registry study in Taiwan. Alzheimer Dis Assoc Disord. 2016; 30:118–22.
14. Driver JA, Beiser A, Au R, Kreger BE, Splansky GL, Kurth T, et al. Inverse association between cancer and Alzheimer’s disease: results from the Framingham Heart Study. BMJ. 2012; 344:e1442.
Article
15. Musicco M, Adorni F, Di Santo S, Prinelli F, Pettenati C, Caltagirone C, et al. Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study. Neurology. 2013; 81:322–8.
Article
16. Wang XM, Walitt B, Saligan L, Tiwari AF, Cheung CW, Zhang ZJ. Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy. Cytokine. 2015; 72:86–96.
Article
17. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007; 4:e296.
Article
18. Kang Y, Na DL, Hahn S. A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients. J Korean Neurol Assoc. 1997; 15:300–8.
19. Choi SH, Na DL, Lee BH, Hahm DS, Jeong JH, Yoon SJ, et al. Estimating the validity of the Korean version of expanded clinical dementia rating (CDR) scale. J Korean Neurol Assoc. 2001; 19:585–91.
20. Choi SH, Na DL, Lee BH, Hahm DS, Jeong JH, Jeong Y, et al. The validity of the Korean version of Global Deterioration Scale. J Korean Neurol Assoc. 2002; 20:612–7.
21. Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol. 2010; 172:1092–7.
Article
22. Parsons LS. Performing a 1: N case-control match on propensity score. Cary, NC: SAS Institute; 2004.
23. Stagg BC, Ehrlich JR, Choi H, Levine DA. Association of cognitive impairment and dementia with receipt of cataract surgery among community-dwelling medicare beneficiaries. JAMA Ophthalmol. 2019; 137:114–7.
Article
24. Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou F, Kalofonos HP. Either called “chemobrain” or “chemofog,” the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manage. 2011; 41:126–39.
Article
25. Jefferis JM, Mosimann UP, Clarke MP. Cataract and cognitive impairment: a review of the literature. Br J Ophthalmol. 2011; 95:17–23.
Article
26. Xiao Z, Wu W, Zhao Q, Liang X, Luo J, Ding D. Association of glaucoma and cataract with incident dementia: a 5-year follow-up in the Shanghai aging study. J Alzheimers Dis. 2020; 76:529–37.
Article
27. Yu WK, Chen YT, Wang SJ, Kuo SC, Shia BC, Liu CJ. Cataract surgery is associated with a reduced risk of dementia: a nationwide population-based cohort study. Eur J Neurol. 2015; 22:1370–7.
Article